← All trials
NCT00005776
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 1995
- Primary completion
- May 1, 1996
- Completion date
- May 1, 1998
- First posted
- —
- Last posted
- —
- Enrollment
- 235
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Child Health and Human Development (NICHD)Lead sponsor
- University of CalgaryOverall official - principal investigator
- Stanford UniversityOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- Wayne State UniversityOverall official - principal investigator
- University of New MexicoOverall official - principal investigator
- University of TennesseeOverall official - principal investigator
- McMaster UniversityOverall official - principal investigator
- University of SydneyOverall official - principal investigator
- University of OttawaOverall official - principal investigator
- Baylor UniversityOverall official - principal investigator
- University of British ColumbiaOverall official - principal investigator
- Brown UniversityOverall official - principal investigator
- Case Western Reserve UniversityOverall official - principal investigator
- University of SaskatchewanOverall official - principal investigator
- Yale UniversityStudy director
- National Center for Research Resources (NCRR)Collaborator
- Medical Research Council of CanadaCollaborator
- George Washington UniversityOverall official - principal investigator
- McGill UniversityOverall official - principal investigator
- Health Sciences Centre Foundation, ManitobaOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.